Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 10/20 | 0.46 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19513454 | 0.86 | KLKB1 (0.43) | KLKB1KMT2ALMNAMAPTKLK1 | |
| SCHEMBL16804397 | 0.85 | CACNA1H (0.43) | KLKB1CACNA1HHSD17B10TSHRMAPK1 | |
| SCHEMBL13813853 | 0.84 | KCNH2 (0.53) | KLKB1HSD17B10TSHRMAPK1KMT2A | |
| SCHEMBL15759268 | 0.84 | KLKB1 (0.51) | KLKB1HSD17B10TSHRMAPK1KMT2A | |
| SCHEMBL17229326 | 0.83 | KLKB1 (0.46) | KLKB1HSD17B10TSHRMAPK1KMT2A | |
| SCHEMBL13102481 | 0.83 | KLKB1 (0.54) | KLKB1KMT2ALMNAMAPTKLK1 | |
| SCHEMBL13800892 | 0.81 | KCNH2 (0.50) | ESRRGHSD17B10TSHRMAPK1KMT2A | |
| SCHEMBL17232474 | 0.81 | KLKB1 (0.49) | KLKB1HSD17B10TSHRMAPK1KMT2A | |
| SCHEMBL16246747 | 0.81 | KLKB1 (0.49) | KLKB1HSD17B10TSHRMAPK1KMT2A | |
| SCHEMBL16246934 | 0.80 | KLKB1 (0.44) | KLKB1HSD17B10KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-05-19 | — | — | US | disclosed |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| US-11198691-B2 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-11084809-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| US-11001578-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-05-11 | — | — | US | disclosed |
| US-20200361923-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | DRI UK LP (KY) | 2020-11-19 | — | — | US | disclosed |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-20200199116-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | DRI UK LP (KY) | 2020-06-25 | — | — | US | disclosed |
| US-20190330200-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS KALLIKREIN INHIBITORS | DRI UK LP (KY) | 2019-10-31 | — | — | US | disclosed |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | DRI UK LP (KY) | 2019-10-03 | — | — | US | disclosed |
| US-9738641-B2 | Bicyclic inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-08-22 | — | — | US | disclosed |
| US-9738641-B2 | Bicyclic inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-08-22 | — | — | US | disclosed |
| US-9670157-B2 | Benzylamine derivatives | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-9670157-B2 | Benzylamine derivatives | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-9533987-B2 | Heterocyclic derivates | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-01-03 | — | — | US | disclosed |
| US-20160185773-A1 | BICYCLIC INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| US-20160168123-A1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-16 | — | — | US | disclosed |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| US-20160039752-A1 | BENZYLAMINE DERIVATIVES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-02-11 | — | — | US | disclosed |
| US-9029407-B2 | Aminothiazole modulators of beta-3-adrenoreceptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | KLKB1 1/4885ESRRG 1781/4885CACNA1H 4796/4885 |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | KLKB1 1/4885ESRRG 1781/4885CACNA1H 4796/4885 |
| US-20160185773-A1 | BICYCLIC INHIBITORS | KLKB1, SERPINB1, BDKRB1 | KLKB1 1/4885ESRRG 3028/4885CACNA1H 4158/4885 |
| US-20200199116-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885ESRRG 1460/4885CACNA1H 4580/4885 |
| US-20160168123-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, SERPINB1, KLK5 | KLKB1 1/4885ESRRG 1781/4885CACNA1H 4796/4885 |
| US-11198691-B2 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885ESRRG 1460/4885CACNA1H 4580/4885 |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | BDKRB1, KLKB1, BDKRB2 | KLKB1 2/4885ESRRG 1190/4885CACNA1H 4764/4885 |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885ESRRG 1355/4885CACNA1H 4424/4885 |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885ESRRG 1580/4885CACNA1H 4565/4885 |
| US-20200361923-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885ESRRG 1460/4885CACNA1H 4580/4885 |
| US-20190330200-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885ESRRG 1460/4885CACNA1H 4580/4885 |
| US-11001578-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885ESRRG 1580/4885CACNA1H 4565/4885 |
| US-11084809-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885ESRRG 1460/4885CACNA1H 4580/4885 |
| US-20160039752-A1 | BENZYLAMINE DERIVATIVES | BDKRB1, BDKRB2, KLKB1 | KLKB1 3/4885ESRRG 2226/4885CACNA1H 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.